Protocol Ledger

NCT07038382 · Phase II · RECRUITING

A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis

Interventional Phase II clinical trial protocol NCT07038382 sponsored by Shanghai Henlius Biotech in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-08-05 Enrollment: 24 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07038382
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)24 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07038382
Protocol FieldVerified Registry Value
NCT IdentifierNCT07038382
Consolidated Lead SponsorShanghai Henlius Biotech
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment24 participants (ESTIMATED)
Registered Start Date2025-08-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI